Last reviewed · How we verify
NCT03041155
Respiratory Muscle Training in Hemodialysis Patients
NA trial testing Muscle respiratory training in Renal Failure in 48 participants. Completed in 20 April 2017.
20 April 2017
Quick facts
| Lead sponsor | Universidade Federal do Ceara |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 48 |
| Start date | 1 February 2017 |
| Primary completion | 20 April 2017 |
| Estimated completion | 20 April 2017 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Muscle respiratory training
Conditions studied
- Renal Failure — all drugs for Renal Failure →
Sponsor
Universidade Federal do Ceara — full company profile →
Who can join
Adults 18 to 65, any sex, with Renal Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The research protocol is a Randomized Clinical Trial that has the effectiveness of a given respiratory muscle training protocol over the indicative variables: Pulmonary function; Markers of oxidative stress and inflammation, endothelial markers and Quality of life in patients with chronic kidney disease undergoing hemodialysis. According to the Investigators, this topic was proposed since it is known that several pulmonary complications occur as a consequence of chronic kidney disease due to uremic myopathy. Therefore, the hypothesis is that the application of a respiratory muscle training protocol will contribute positively pulmonary functionality and a decrease in oxidative stress and inflammation in chronic kidney patients, consequently, will bring improvement in the quality of life for these patients. The Patients will be divided into two groups: control group - No intervention of the Muscular Training (CG) And Intervention Group (GI). The intervention protocol will be composed of respiratory muscle training And lasts for two (2) months, with three (3) visits per week. It will be carried out through Threshold PeP appliance. The twelve (12) first training sessions will have a total duration of 30 minutes 15 minutes with inspiratory load of 20 cmH2O and 15 minutes with expiratory load of 20 CmH 2 O; and the others (12) twelve sessions will last 40 minutes each, with 20 minutes with an inspiratory load of 20 CmH2O and 20 minutes with expiratory load of 20 cmH2O. The variables evaluated will be: muscular strength Respiratory (maximum inspiratory pressure and maximum expiratory pressure - Pimáx and Pemáx); Lung function (Slow Vital Capacity - CVL, forced expiratory volume in the first minute - VEF1, Vital Capacity Forced - CVF and Maximum Voluntary Ventilation - VVM); Serum levels of oxidative stress markers, endothelial markers and endothelin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03041155
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Failure
Currently open trials in the same condition.
- NCT07293936 — Post-Filter Hematocrit · NA · recruiting
- NCT06814327 — Assessment of Organ Failure Risk Predictions in ICU · active not recruiting
- NCT06203977 — Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) · Phase 1 · recruiting
- NCT06142396 — Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure · EARLY_PHASE1 · recruiting
- NCT06620523 — Prevent Cardiac Surgery Associated AKI Trial · Phase 2 · recruiting
Other Universidade Federal do Ceara trials
Trials by the same sponsor.
- NCT06147271 — Impact of SGLT2 Inhibitors in Heart Transplant Recipients · Phase 2 · enrolling by invitation
- NCT07273578 — HOME BLOOD PRESSURE MONITORING IN PATIENTS WITH UNCONTROLLED HYPERTENSION: A RANDOMIZED CLINICAL TRIAL · NA · completed
- NCT04928495 — Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19 · Phase 3 · unknown
- NCT03281421 — Immediate Effects of Ankle Mobilization on Dorsiflexion Range of Motion in Women With Patellofemoral Pain. · NA · completed
- NCT03163290 — Effect of Two Strengthening Protocols for Lower Limbs in Patients With Patellofemoral Pain · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03041155 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidade Federal do Ceara
- Last refreshed: 19 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03041155.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing